Lee G Wilke, MD, FACS


  • Senior Medical Director, Clinical Cancer Services; UW Health/UW Carbone Cancer Center
  • Professor, Division of Surgical Oncology
  • Hendricks Chair in Breast Cancer Surgery Research
  • Vice Chair of Research; UW Department of Surgery

(608) 263-7064

  • Administrative Assistant: (608) 262-2025

600 Highland Avenue
Box 7375 Clinical Science Center
Madison, WI 53792


  • MD, Duke University, Durham, NC, 1993
  • Residency in Surgery, University of Michigan, Ann Arbor, Michigan, 1993-2000
  • ACS Resident Research Fellow in Immunotherapy, University of Michigan, Ann Arbor, MI 1996-1998

Clinical Specialties

Dr. Wilke is certified by the American Board of Surgery and specializes in benign and malignant diseases of the breast; sentinel lymph-node mapping; neoadjuvant therapy for breast cancer; and oncoplastic breast surgery.

Research Interests

Dr. Wilke’s principal research interest is in clinical trials seeking novel methods of treating patients with breast cancer. Dr. Wilke is lead Principal investigator for the UW Carbone Cancer Center NCTN Lead Academic Program UG1 Grant and a Board member for the NCCN and NAPBC. She is a collaborator on multiple grants and trials evaluating novel medical and surgical treatments for breast cancer.

Recent Publications

  • Reexamining Time From Breast Cancer Diagnosis to Primary Breast Surgery.
    Wiener AA, Hanlon BM, Schumacher JR, Vande Walle KA, Wilke LG, Neuman HB
    JAMA Surg 2023 May 01; 158(5): 485-492
    [PubMed ID: 36857045]

  • Clinical Trials That Have Informed the Modern Management of Breast Cancer.
    Krecko LK, Lautner MA, Wilke LG
    Surg Oncol Clin N Am 2023 Jan; 32(1): 27-46
    [PubMed ID: 36410920]

  • Changing Landscape of Breast Cancer Management.
    Seydel AS, Wilke LG
    Surg Clin North Am 2023 Feb; 103(1): xv-xvi
    [PubMed ID: 36410358]

  • Genomic Profiling and Liquid Biopsies for Breast Cancer.
    Marcinak CT, Murtaza M, Wilke LG
    Surg Clin North Am 2023 Feb; 103(1): 49-61
    [PubMed ID: 36410353]

  • Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer.
    Hu Y, Manasrah BK, McGregor SM, Lera RF, Norman RX, Tucker JB, Scribano CM, Yan RE, Humayun M, Wisinski KB, Tevaarwerk AJ, O'Regan RM, Wilke LG, Weaver BA, Beebe DJ, Jin N, Burkard ME
    Mol Cancer Ther 2021 Dec; 20(12): 2553-2567
    [PubMed ID: 34583980]

All Publications on PubMed